Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Bucladesine in Severe Methylmalonic Acidemia (McAMP)
jRCT2041210065Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bucladesine in methylmalonic acidemia (MMA), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Suspected adverse reaction rate. Started Mar 2022; status: completed.
02
Drugs
bucladesine
03
Conditions
methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on jRCT2041210065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210065.